| 31 | COVID-19 |
| 27 | Humans |
| 13 | pandemic |
| 11 | Influenza, Human (epidemiology) |
| 11 | Covid-19 |
| 10 | Pandemics |
| 9 | France |
| 8 | covid-19 |
| 8 | Influenza, Human (virology) |
| 8 | History, 20th Century |
| 8 | Coronavirus |
| 8 | Coronavirus Infections (epidemiology) |
| 8 | Betacoronavirus |
| 7 | SARS-CoV-2 |
| 7 | Pneumonia, Viral (epidemiology) |
| 7 | Male |
| 7 | Influenza, Human (prevention & control) |
| 7 | Influenza, Human (history) |
| 6 | virus |
| 6 | mobility |
| 6 | geography |
| 6 | epidemic |
| 6 | Vaccine |
| 6 | Female |
| 6 | China |
| 5 | pollution |
| 5 | health |
| 5 | Wuhan |
| 5 | Pandemics (prevention & control) |
| 5 | Italy |
| 5 | Influenza |
| 4 | urban economy |
| 4 | transport |
| 4 | territories |
| 4 | telework |
| 4 | public health |
| 4 | local development |
| 4 | internal migration |
| 4 | economy |
| 4 | economic geography |
| 4 | cities |
| 4 | World Health Organization |
| 4 | Phylogeny |
| 4 | Pandemics (history) |
| 4 | Influenza Pandemic, 1918-1919 (history) |
| 4 | Influenza A virus |
| 4 | Immunological adjuvant |
| 4 | Europe |
| 4 | Epidemiology |
| 4 | Animals |
| 3 | vulnerability |
| 3 | value chains |
| 3 | telecommunications |
| 3 | risk |
| 3 | repatriation |
| 3 | pandémie |
| 3 | lockdown |
| 3 | international migration |
| 3 | floating population |
| 3 | coronavirus |
| 3 | containment |
| 3 | confinement |
| 3 | circular economy |
| 3 | Taiwan |
| 3 | Quarantine |
| 3 | Pneumonia, Viral (transmission) |
| 3 | Pandemic |
| 3 | Influenza, Human (microbiology) |
| 3 | Influenza Vaccines (immunology) |
| 3 | Influenza Pandemic, 1918-1919 |
| 3 | Influenza A |
| 3 | Influenza A Virus, H1N1 Subtype |
| 3 | Influenza A Virus, H1N1 Subtype (genetics) |
| 3 | Infection |
| 3 | History, 21st Century |
| 3 | Evolution, Molecular |
| 3 | Epidemics |
| 3 | Disease Outbreaks |
| 3 | Coronavirus Infections (virology) |
| 3 | Coronavirus Infections (transmission) |
| 3 | Child |
| 3 | Asia |
| 3 | Aids |
| 3 | Adult |
| 2 | immunity |
| 2 | epidemiology |
| 2 | enseignement à distance |
| 2 | demography |
| 2 | crise sanitaire |
| 2 | covid-19 pandemic |
| 2 | conditions de logement |
| 2 | age |
| 2 | United States |
| 2 | United States (epidemiology) |
| 2 | United Kingdom (epidemiology) |
| 2 | Seasons |
| 2 | SIR model |
| 2 | Respiratory Protective Devices |
| 2 | Psycholinguistics |
| 2 | Population Surveillance |
| 2 | Pneumonia, Viral |
| 2 | Pneumonia, Viral (virology) |
| 2 | Pneumonia, Viral (prevention & control) |
| 2 | Mutation |
| 2 | Mortalité |
| 2 | Middle Aged |
| 2 | Logement |
| 2 | Influenza, Human (transmission) |
| 2 | Influenza A virus (genetics) |
| 2 | Human |
| 2 | Hemagglutinin Glycoproteins, Influenza Virus (genetics) |
| 2 | Emergencies |
| 2 | Disease Outbreaks (history) |
| 2 | Covid-19 pandemic |
| 2 | Coronavirus Infections (prevention & control) |
| 2 | Child, Preschool |
| 2 | Avian influenzavirus |
| 2 | Adolescent |
| 1 | état d'urgence sanitaire |
| 1 | épidemie |
| 1 | zigzag strategy |
| 1 | working class |
| 1 | welfare measure |
| 1 | voisinage |
| 1 | virophagy |
| 1 | ville |
| 1 | travail |
| 1 | travail à distance |
| 1 | tests |
| 1 | telemedicine |
| 1 | telehealth |
| 1 | surveillance |
| 1 | sub-national allocation of tests |
| 1 | spatial planning |
| 1 | solidarité |
| 1 | software architecture |
| 1 | simultaneous shocks |
| 1 | savings |
| 1 | sARS-CoV-2 |
| 1 | résilience |
| 1 | reproduction number 1 |
| 1 | recession |
| 1 | real-time Analysis |
| 1 | radiology |
| 1 | quality of government |
| 1 | public health system |
| 1 | public health support |
| 1 | public health emergency of international concern |
| 1 | public deficit |
| 1 | public debt |
| 1 | psychotrauma |
| 1 | predictive |
| 1 | pneumonia |
| 1 | performance |
| 1 | pediatric pulmonology |
| 1 | passenger-generated data |
| 1 | passenger-centric metrics |
| 1 | paraproteinemic neuropathy |
| 1 | pandémie Covid 19 |
| 1 | pandemic influenza plan |
| 1 | outbreak |
| 1 | operations research |
| 1 | oil price war |
| 1 | nuptiality |
| 1 | numérique |
| 1 | non-pharmaceutical interventions |
| 1 | non-communicable disease |
| 1 | natural gas JEL Classification: |
| 1 | natality |
| 1 | multifocal motor neuropathy |
| 1 | multifactorial disease |
| 1 | mortality |
| 1 | mobile health |
| 1 | minorités ethniques et raciales |
| 1 | migration |
| 1 | microbial shock |
| 1 | mental health |
| 1 | memory effects |
| 1 | mechanistic-statistical model |
| 1 | mathematical modelling |
| 1 | macroeconomic drivers |
| 1 | m-health |
| 1 | logement social |
| 1 | linear programming |
| 1 | inégalités sociales |
| 1 | international economy |
| 1 | interdisciplinary research |
| 1 | inflation |
| 1 | inflammation |
| 1 | infectious disease |
| 1 | infectious disease control |
| 1 | income transfers |
| 1 | immunology |
| 1 | image detection |
| 1 | herd immunity |
| 1 | health spending |
| 1 | health risk |
| 1 | health infrastructure |
| 1 | health education |
| 1 | health crisis |
| 1 | health crisis management |
| 1 | guerre |
| 1 | grippe espagnole |
| 1 | forme scolaire |
| 1 | fatalities |
| 1 | epidemics |
| 1 | epidemic prevention and control |
| 1 | epidemic model |
| 1 | epidemic dynamics |
| 1 | environnment |
| 1 | entraide |
| 1 | enquête COCONEL |
| 1 | enfants |
| 1 | emergency planning |
| 1 | efficiency criterion |
| 1 | effective reproduction number |
| 1 | ecotoxicology |
| 1 | e-health |
| 1 | dysimmune |
| 1 | drop oil price |
| 1 | dollar |
| 1 | disparity |
| 1 | discrete time modelling |
| 1 | digital medicine |
| 1 | digital health |
| 1 | deconfinement |
| 1 | deceleration of harm |
| 1 | data analysis |
| 1 | daily reproduction number |
| 1 | crude oil |
| 1 | countermeasure evaluation |
| 1 | coronavirus 2 |
| 1 | continuité pédagogique |
| 1 | conflits potentiels |
| 1 | conditions de vie |
| 1 | compartmental models |
| 1 | comparative public administration |
| 1 | chronic inflammatory demyelinating polyneuropathy |
| 1 | choc microbien |
| 1 | austerity policies |
| 1 | artificial intelligence |
| 1 | and Resilience |
| 1 | acceleration of harm |
| 1 | Zoonoses (transmission) |
| 1 | Zoonoses (history) |
| 1 | Young Adult |
| 1 | X-ray |
| 1 | World War I |
| 1 | West Africa |
| 1 | Virus like particle |
| 1 | Virus Shedding |
| 1 | Virus Diseases (transmission) |
| 1 | Virus Diseases (history) |
| 1 | Virulence (genetics) |
| 1 | Viral disease |
| 1 | Vaccine tablet |
| 1 | Vaccine strain |
| 1 | Vaccination |
| 1 | United States Food and Drug Administration |
| 1 | United States Department of Veterans Affairs |
| 1 | Uncertainty |
| 1 | U.S. economy |
| 1 | Télétravail contraint |
| 1 | Turkey |
| 1 | Triage |
| 1 | Triage (methods) |
| 1 | Triage (ethics) |
| 1 | Travel (legislation & jurisprudence) |
| 1 | Transmission |
| 1 | Transmission dynamics |
| 1 | Thrombosis |
| 1 | Testing |
| 1 | Territorial vulnerabilities |
| 1 | Technology |
| 1 | Tablets |
| 1 | TVP-SVAR model |
| 1 | TSPT |
| 1 | Swine |
| 1 | Sustainability |
| 1 | Surgical complications |
| 1 | Statement |
| 1 | Sports |
| 1 | Species Specificity |
| 1 | Spatio-Temporal Analysis |
| 1 | Spatial Analysis |
| 1 | Spanish flu |
| 1 | South America (epidemiology) |
| 1 | Socioeconomic Factors |
| 1 | Social network analysis |
| 1 | Social distancing |
| 1 | Social Isolation |
| 1 | Simulation |
| 1 | Sidechain |
| 1 | Severe acute respiratory syndrome |
| 1 | Severe Acute Respiratory Syndrome (history) |
| 1 | Sequence analysis |
| 1 | Sensitivity |
| 1 | Selection, Genetic |
| 1 | Schools |
| 1 | Sampling Studies |
| 1 | STRATEGIC ANALYSIS |
| 1 | SOC |
| 1 | SEN |
| 1 | SARS |
| 1 | SARS-CoV |
| 1 | SARS Virus |
| 1 | S&P GS commodities Indexes |
| 1 | Romania |
| 1 | Risk perception |
| 1 | Risk Assessment |
| 1 | Reverse transcription polymerase chain reaction |
| 1 | Retrospective Studies |
| 1 | Respiratory Distress Syndrome, Newborn (therapy) |
| 1 | Respiratory Distress Syndrome, Newborn (diagnosis) |
| 1 | Respiration, Artificial (methods) |
| 1 | Respiration, Artificial (ethics) |
| 1 | Resilient ethics Affiliations |
| 1 | R program |
| 1 | Public health |
| 1 | Public Health Policy |
| 1 | Public Health (legislation & jurisprudence) |
| 1 | Public Health (history) |
| 1 | Protein Conformation |
| 1 | Protein Array Analysis (methods) |
| 1 | Prognosis |
| 1 | Prevention |
| 1 | Prevalence |
| 1 | Predisposition |
| 1 | Pre-clinical evaluation |
| 1 | Poverty |
| 1 | Porine |
| 1 | Polymerase chain reaction |
| 1 | Poisson regression |
| 1 | Pneumonia, Viral (mortality) |
| 1 | Pneumonia (therapy) |
| 1 | Pneumonia (diagnosis) |
| 1 | Pneumococcus |
| 1 | Pig |
| 1 | Phylogeography |
| 1 | Phylogenetic analysis |
| 1 | Phototherapy (methods) |
| 1 | Peste noire |
| 1 | Penicillin-binding proteins |
| 1 | Patient-Centered Care |
| 1 | Paris |
| 1 | Pandemics (statistics & numerical data) |
| 1 | PTSD |
| 1 | Outbreak |
| 1 | Orthomyxoviridae Infections |
| 1 | Orthomyxoviridae (isolation & purification) |
| 1 | Orthomyxoviridae (immunology) |
| 1 | Orthomyxoviridae (genetics) |
| 1 | Organizational Policy |
| 1 | Optimism bias |
| 1 | Optimal control |
| 1 | Optimal Control |
| 1 | One health |
| 1 | Odds Ratio |
| 1 | Obesity (virology) |
| 1 | Obesity (physiopathology) |
| 1 | Obesity (immunology) |
| 1 | Obesity (epidemiology) |
| 1 | Novel coronavirus |
| 1 | Nigeria |
| 1 | Narcolepsy (immunology) |
| 1 | NAIRU |
| 1 | Myocarditis (therapy) |
| 1 | Myocarditis (diagnosis) |
| 1 | Multimorbidity |
| 1 | Multidrug resistance bacteria |
| 1 | Mucosal vaccination |
| 1 | Mouth Mucosa |
| 1 | Mouse |
| 1 | Mortality |
| 1 | Moral values |
| 1 | Monetary policy |
| 1 | Molecular epidemiology |
| 1 | Molecular Sequence Data |
| 1 | Models, Theoretical |
| 1 | Models, Molecular |
| 1 | Models, Biological |
| 1 | Middle East Respiratory Syndrome Coronavirus |
| 1 | Microbiology |
| 1 | Mechanisms |
| 1 | Mean Field Games |
| 1 | Mathematical model |
| 1 | Mass Casualty Incidents |
| 1 | MERS |
| 1 | MERS-CoV |
| 1 | Lung |
| 1 | Lung Diseases (virology) |
| 1 | Lung Diseases (therapy) |
| 1 | Lung Diseases (epidemiology) |
| 1 | Low-income workers |
| 1 | Low-Level Light Therapy |
| 1 | Lockdown |
| 1 | Likelihood Functions |
| 1 | Light |
| 1 | Latin America (epidemiology) |
| 1 | Lateral gene transfers |
| 1 | Italy (epidemiology) |
| 1 | Israel |
| 1 | IoT - Internet of Things |
| 1 | Intramuscular |
| 1 | Interference |
| 1 | Intensive care unit |
| 1 | Intensive Care Unit (ICU) |
| 1 | Instagram |
| 1 | Injections |
| 1 | Infrared Rays |
| 1 | Influenzavirus A(H1N1) |
| 1 | Influenza, Human (mortality) |
| 1 | Influenza, Human (ethnology) |
| 1 | Influenza, Human (drug therapy) |
| 1 | Influenza, Human (complications) |
| 1 | Influenza virus |
| 1 | Influenza Vaccines |
| 1 | Influenza Vaccines (genetics) |
| 1 | Influenza Vaccines (adverse effects) |
| 1 | Influenza Vaccines (administration & dosage) |
| 1 | Influenza Pandemic, 1918-1919 (statistics & numerical data) |
| 1 | Influenza A virus (pathogenicity) |
| 1 | Influenza A virus (metabolism) |
| 1 | Influenza A Virus |
| 1 | Influenza A Virus, H5N1 Subtype |
| 1 | Influenza A Virus, H5N1 Subtype (pathogenicity) |
| 1 | Influenza A Virus, H1N1 Subtype (isolation & purification) |
| 1 | Influenza A Virus, H1N1 Subtype (immunology) |
| 1 | Influenza A Virus, H1N1 Subtype (drug effects) |
| 1 | Influenza A (H1N1) |
| 1 | Infectious diseases |
| 1 | Infant |
| 1 | Infant, Premature |
| 1 | Infant, Newborn |
| 1 | Industrial accidents |
| 1 | Indonesia |
| 1 | Indian |
| 1 | India |
| 1 | Incidence |
| 1 | Immunoprophylaxis |
| 1 | Hypertension |
| 1 | Humoral immunity |
| 1 | Housing |
| 1 | Hospitals, Packaged |
| 1 | History, Modern 1601- |
| 1 | History, 19th Century |
| 1 | Hemagglutinins (metabolism) |
| 1 | Hemagglutinins (genetics) |
| 1 | Hemagglutinins (chemistry) |
| 1 | Hemagglutinin |
| 1 | Hemagglutinin Glycoproteins, Influenza Virus (immunology) |
| 1 | Heliotherapy |
| 1 | Heart failure |
| 1 | Healthcare Disparities (ethnology) |
| 1 | Health system |
| 1 | Health Status Disparities |
| 1 | Health Services Accessibility (statistics & numerical data) |
| 1 | Health Care Surveys (statistics & numerical data) |
| 1 | Health Blockchain |
| 1 | Health Behavior |
| 1 | Hallucinations |
| 1 | Haiti |
| 1 | HIV-1 |
| 1 | H1N1 influenza |
| 1 | H1N1 Subtype |
| 1 | Government |
| 1 | Government Regulation |
| 1 | Global Health |
| 1 | Genetic vaccine |
| 1 | Genetic epidemiology |
| 1 | Genetic Variation |
| 1 | Gene Expression Regulation, Viral (physiology) |
| 1 | GDP |
| 1 | Fomites (microbiology) |
| 1 | Flulike syndrome |
| 1 | Fixed-effects model |
| 1 | Face protection masks |
| 1 | FORESEEABLE TECHNOLOGICAL TRANSFER |
| 1 | Exploitative conduct |
| 1 | Evolutionary rate |
| 1 | Evolutionary genetics |
| 1 | Evolution |
| 1 | Ethics of resilience |
| 1 | Etats-Unis |
| 1 | Epidémie |
| 1 | Epidemic |
| 1 | Epidemic control |
| 1 | England |
| 1 | EcoHealth |
| 1 | Earthquakes |
| 1 | Dépression |
| 1 | Disease Transmission, Infectious |
| 1 | Disease Outbreaks (prevention & control) |
| 1 | Disease Models, Animal |
| 1 | Disaster management |
| 1 | Disaster Information |
| 1 | Digestive surgery |
| 1 | Diagnosis-Related Groups |
| 1 | Detection |
| 1 | Detection of Infectious Diseases |
